drugset

Drugs / AOH1996

Follow last change Jul 2025 re-read 9 days ago

AOH1996

also known as Proliferating Cell Nuclear Antigen Inhibitor AOH1996

targets PCNA via inhibition

Developed for: acute myeloid leukemia · leiomyosarcoma · malignant pancreatic neoplasm · non-small cell lung carcinoma · osteosarcoma · ovarian cancer · refractory malignant neoplasm · synovial sarcoma
Investigated by: City of Hope Medical Center · National Cancer Institute (NCI)

Trials 2

today NCT06763341 · Ph 1 NCT05227326 · Ph 1

2023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06763341	Jul 2025 → Jan 2027 expected	acute myeloid leukemia	City of Hope Medical Center	Recruiting	No outcome recorded
Phase 1	NCT05227326	Aug 2022 → Sep 2029 expected	leiomyosarcoma, malignant pancreatic neoplasm, non-small cell lung carcinoma, osteosarcoma +3	City of Hope Medical Center	Recruiting	No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	AOH1996	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06763341 ↗ 1 NCT05227326 ↗
Known as	Proliferating Cell Nuclear Antigen Inhibitor AOH1996	“Proliferating Cell Nuclear Antigen Inhibitor AOH1996” NCT05227326 ↗
Action	Inhibit	“PCNA inhibitor AOH1996” NCT05227326 ↗
Route	Oral	“Given PO” NCT05227326 ↗
Target	PCNA	“PCNA inhibitor AOH1996” NCT05227326 ↗